Drug Profile
Breast cancer vaccine - MabVax/MSKCC
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Class Cancer vaccines
- Mechanism of Action CA-19-9 antigen modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Breast-cancer in USA (SC, Injection)
- 08 Jul 2014 MabVax Therapeutics merged with a wholly-owned subsidiary of Telik
- 18 Dec 2008 Phase-I clinical trials in Breast cancer in USA (SC)